Syed Bokhari, MD
Interventional Cardiology · London, KYNPI 1831382399
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (52.1%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) at 55.7% of the total. Reporting peaked in 2019 at $2,350 and has fallen 85.2% since, to $349 in 2025. That places this record below the midpoint for interventional cardiology clinicians in KY, where the typical reported total is $7,951.
Across 120 payments — averaging $47.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$3K
- Terumo Medical Corporation$543
- Novartis$486
- Pfizer$387
- Merck$212
- Actelion Pharmaceuticals US, Inc.$117
- plus $804 from 18 others
Across 4 payments — averaging $6448.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$26K
What the payments were for
- Speaking & faculty fees$3,00052%
- Travel & lodging$5439%
- Food & beverage$2,11637%
- Education$992%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 15 | $3,209 |
| Terumo Medical Corporation | 1 | $543 |
| Novartis | 27 | $486 |
| Pfizer | 25 | $387 |
| Merck | 13 | $212 |
| Actelion Pharmaceuticals US, Inc. | 2 | $117 |
| AstraZeneca | 6 | $115 |
| Amgen | 5 | $101 |
| EKOS Corporation | 2 | $83 |
| Sanofi-aventis U.S. LLC | 4 | $78 |
| Biohaven Pharmaceuticals, Inc. | 1 | $69 |
| Baxter Healthcare | 2 | $51 |
| Boehringer Ingelheim | 4 | $50 |
| Boston Scientific | 3 | $50 |
| Medtronic | 1 | $49 |
| Abiomed | 1 | $36 |
| Alkermes, Inc. | 1 | $21 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $18 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $16 |
| Cook Medical LLC | 1 | $14 |
| Abbott | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Altathera Pharmaceuticals LLC | 1 | $13 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LifeVest$3,000
- Navicross$543
- Glidesheath$543
- GlideWire$543
How this compares
$5,758 in reported general payments places this provider in the 35th percentile of 129 interventional cardiology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 69 | $64,971 |
| EntrestoSacubitril/Valsartan | 33 | $37,316 |
| BrilintaTicagrelor | 48 | $36,457 |
| Repatha SureclickEvolocumab | 25 | $21,847 |
| Ranolazine ErRanolazine | 60 | $5,205 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 118 | $1,117 |
| ClopidogrelClopidogrel Bisulfate | 88 | $647 |
| Metoprolol Tartrate | 130 | $608 |
| Rosuvastatin Calcium | 84 | $597 |
| Atorvastatin Calcium | 58 | $458 |
| Valsartan | 43 | $416 |
| Omega-3 Acid Ethyl Esters | 13 | $293 |
| Nitroglycerin | 17 | $285 |
| Eplerenone | 11 | $241 |
| Metoprolol Succinate | 34 | $233 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $387 | $64,97169 claims |
| NovartisEntresto | $486 | $37,31633 claims |
| AstraZenecaBrilinta | $115 | $36,45748 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 129 interventional cardiology providers in Kentucky.
Other interventional cardiology in London
- Mirza AhmedLondon$20K
- Amit SrivastavaEdgewood$642K
- Avichai EresLexington$616K
- Steve LinLexington$362K
- Daniel StewartLouisville$290K
- Robert SawyerLexington$249K
- Ganesh Keshav ThirunavukkarasuLexington$220K
- Daniel RothschildLouisville$154K
- Naresh SolankhiLouisville$132K
- Ashish RastogiOwensboro$123K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.